Two Sigma Advisers’s Edwards Lifesciences EW Stock Holding History

Two Sigma Advisers’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-54,000	Closed	-$592K	–	2340
2013 Q4	$592K	Buy	+54,000	New	+$609K	0.01%	1498

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Two Sigma Advisers's EW Position: Q1 2026 in Review

Two Sigma Advisers sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 110,006 shares — an estimated $9.38M sold.

Two Sigma Advisers first reported a position in EW in Q3 2013 and held it in 42 quarters. The position peaked at $261M in Q4 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Two Sigma Advisers reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 110,006 Edwards Lifesciences shares in Q1 2026, an estimated $9.38M.
Two Sigma Advisers first reported a position in Edwards Lifesciences in Q3 2013 and held it in 42 quarters.
Two Sigma Advisers's Edwards Lifesciences position peaked at $261M in Q4 2022.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.